ZA929632B - Chemical compounds. - Google Patents

Chemical compounds.

Info

Publication number
ZA929632B
ZA929632B ZA929632A ZA929632A ZA929632B ZA 929632 B ZA929632 B ZA 929632B ZA 929632 A ZA929632 A ZA 929632A ZA 929632 A ZA929632 A ZA 929632A ZA 929632 B ZA929632 B ZA 929632B
Authority
ZA
South Africa
Prior art keywords
atoms
contg
esp
ring members
linked
Prior art date
Application number
ZA929632A
Other languages
English (en)
Inventor
Gary James Bridger
Sreenivasan Padmanabhan
Renato Tony Skerlj
David Michael Thornton
Original Assignee
Johnson Matthey Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10706343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA929632(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson Matthey Plc filed Critical Johnson Matthey Plc
Publication of ZA929632B publication Critical patent/ZA929632B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Liquid Crystal Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA929632A 1991-12-16 1992-12-11 Chemical compounds. ZA929632B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919126677A GB9126677D0 (en) 1991-12-16 1991-12-16 Improvements in chemical compounds

Publications (1)

Publication Number Publication Date
ZA929632B true ZA929632B (en) 1993-06-18

Family

ID=10706343

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA929632A ZA929632B (en) 1991-12-16 1992-12-11 Chemical compounds.

Country Status (26)

Country Link
US (2) US5583131A (fr)
EP (2) EP0619813B1 (fr)
JP (1) JP3375961B2 (fr)
KR (1) KR100286235B1 (fr)
AT (1) ATE273964T1 (fr)
AU (1) AU661086B2 (fr)
CA (1) CA2125978C (fr)
CZ (1) CZ286928B6 (fr)
DE (2) DE69233401T2 (fr)
DK (1) DK0619813T3 (fr)
ES (1) ES2224096T3 (fr)
FI (1) FI942849A (fr)
GB (1) GB9126677D0 (fr)
HK (2) HK1014368A1 (fr)
HU (1) HU224013B1 (fr)
IL (1) IL103984A (fr)
MX (1) MX9207316A (fr)
MY (1) MY110897A (fr)
NL (1) NL300425I1 (fr)
NO (2) NO305984B1 (fr)
NZ (1) NZ246179A (fr)
PL (1) PL173643B1 (fr)
PT (1) PT619813E (fr)
RU (1) RU94031208A (fr)
WO (1) WO1993012096A1 (fr)
ZA (1) ZA929632B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9318550D0 (en) * 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5663161A (en) 1995-02-17 1997-09-02 The Research Foundation Of State University Of New York Anti-viral triaza compounds
US5612478A (en) * 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) * 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5608061A (en) * 1995-08-02 1997-03-04 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
AU1732900A (en) 1998-11-17 2000-06-05 Ligand Pharmaceuticals Incorporated Methods of treating thrombocytopenia
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
ES2265923T3 (es) * 1999-03-24 2007-03-01 Anormed Inc. Compuestos heterociclicos que se unen a receptores de quimiocinas.
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
JP2002543126A (ja) * 1999-05-03 2002-12-17 スミスクライン・ビーチャム・コーポレイション Ｃｘｃｒ−４受容体アンタゴニスト−トロンボポエチン模倣物
EP1244648B1 (fr) * 1999-12-17 2009-04-15 Genzyme Corporation Recepteur de chemokine liant des composes heterocycliques
AU2001233290A1 (en) * 2000-02-22 2001-09-03 Brewer Science, Inc. Organic polymeric antireflective coatings deposited by chemical vapor deposition
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
CA2419224A1 (fr) * 2000-09-15 2002-03-21 Anormed Inc. Composes heterocycliques se liant avec les recepteurs de chimiokines
NZ524651A (en) 2000-09-15 2005-08-26 Anormed Inc Chemokine receptor binding heterocyclic compounds for the treatment of HIV or FIV
PL359292A1 (en) 2000-09-29 2004-08-23 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
DE10117206A1 (de) * 2001-04-06 2002-10-10 Bayer Ag Verfahren zur Herstellung von halogensubstituierten Dibenzylalkoholen, diese halogensubstituierten Dibenzylalkohole sowie deren Verwendung
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
SI1411918T1 (sl) * 2001-07-31 2012-04-30 Genzyme Global S A R L Postopki za mobilizacijo progenitorskih/matičnih celic
CN1272322C (zh) * 2001-09-12 2006-08-30 阿诺麦德股份有限公司 对映体纯的氨基取代稠合双环的合成
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
MXPA04006136A (es) * 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
DK1466912T3 (da) * 2002-01-18 2013-07-01 Astellas Pharma Inc 2-acylaminothiazolderivat eller salt deraf
US7291631B2 (en) * 2003-04-11 2007-11-06 Genzyme Corporation CXCR4 chemokine receptor binding compounds
CN101941964A (zh) * 2003-04-22 2011-01-12 阿诺麦德股份有限公司 具有促进功效的趋化因子受体结合的杂环化合物
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
EP1708703A4 (fr) * 2003-12-11 2008-04-09 Anormed Inc Composes de liaison aux recepteurs de la chemokine
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
EP1730113B1 (fr) * 2004-03-15 2016-12-28 Genzyme Corporation Procede de synthese d'un antagoniste de cxcr4
EP1783108B1 (fr) * 2004-08-05 2010-12-22 Sumitomo Chemical Company, Limited Methode de production d'un benzenedimethanol halogene-substitue
WO2006020891A2 (fr) * 2004-08-13 2006-02-23 Anormed Inc. Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
JP2008519052A (ja) * 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
CA2612325A1 (fr) * 2005-06-15 2006-12-28 Anormed Inc. Composes de liaison au recepteur de la chimiokine
CA2619881A1 (fr) * 2005-08-16 2007-02-22 Genzyme Corporation Composes se liant aux recepteurs de chimiokine
BRPI0615180A2 (pt) * 2005-08-19 2011-05-03 Genzyme Corp método para intensificar a quimioterapia
WO2007054783A2 (fr) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions et procedes de traitement de la thrombocytopenie
ZA200806108B (en) 2006-01-24 2009-10-28 Sumitomo Chemical Co Method for producing halogen-substituted benzenedi-methanol
US20100035941A1 (en) * 2006-02-24 2010-02-11 Bridger Gary J Methods for increasing blood flow and/or promoting tissue regeneration
AR063470A1 (es) * 2006-08-02 2009-01-28 Genzyme Corp Terapia combinada
CA2659337A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Therapie combinee
WO2008021283A2 (fr) * 2006-08-08 2008-02-21 Akarx, Inc. Compositions et méthodes pour l'augmentation de la concentration en plaquettes sanguines chez l'homme
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
CA2688504A1 (fr) 2007-06-18 2008-12-24 Children's Hospital & Research Center At Oakland Procede permettant d'isoler du placenta des cellules souches et progenitrices
US9241898B2 (en) 2008-03-11 2016-01-26 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
EP2149567A1 (fr) * 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Composé pour la liaison de phosphatidylsérine
US8771677B2 (en) * 2008-12-29 2014-07-08 Vladimir B Serikov Colony-forming unit cell of human chorion and method to obtain and use thereof
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
WO2013082529A1 (fr) 2011-12-02 2013-06-06 Yale University Synthèse enzymatique de poly(amine-co-esters) et ses méthodes d'utilisation pour une libération de gènes
WO2014125499A1 (fr) 2013-02-13 2014-08-21 Natco Pharma Limited Procédé amélioré et commercialement viable pour la préparation de plérixafor base de haute pureté
PT107018A (pt) * 2013-06-20 2014-12-22 Inst Superior Técnico Síntese e uso de ciclamas com atividade antibacteriana
EP3038617A1 (fr) 2013-08-30 2016-07-06 Ramot at Tel-Aviv University Ltd. Méthode pour traiter la sclérose latérale amyotrophique par inhibition de la signalisation cxcr4/cxcl12
US10272019B2 (en) 2014-05-09 2019-04-30 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10682422B2 (en) 2014-11-18 2020-06-16 Yale University Formulations for targeted release of agents under low pH conditions and methods of use thereof
WO2016081621A1 (fr) 2014-11-18 2016-05-26 Yale University Formulations à libération ciblée d'agents sous des conditions de ph bas, et procédés d'utilisation de celles-ci
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
MX2017013668A (es) 2015-04-25 2018-07-06 Massachusetts Gen Hospital Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
US10933049B2 (en) 2015-06-03 2021-03-02 The University Of Queensland Mobilizing agents and uses therefor
KR20180043360A (ko) 2015-09-02 2018-04-27 프레세니어스 카비 온콜로지 리미티드 자일렌 결합된 사이클램 화합물의 제조방법
US11890348B2 (en) 2015-09-18 2024-02-06 The General Hospital Corporation Localized delivery of anti-fugetactic agent for treatment of cancer
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
EP3389652B1 (fr) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2017106630A1 (fr) 2015-12-18 2017-06-22 The General Hospital Corporation Polymères polyacétal, conjugués, particules et utilisations associées
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
WO2017143061A1 (fr) 2016-02-16 2017-08-24 Yale University Compositions et procédés pour le traitement de la mucoviscidose
CN109476706A (zh) 2016-02-16 2019-03-15 耶鲁大学 用于促进靶向基因编辑的组合物及其使用方法
EP3440112A4 (fr) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2017197128A1 (fr) 2016-05-11 2017-11-16 Yale University Nanoparticules de poly(amine-co-ester) et leurs procédés d'utilisation
EP3471726A4 (fr) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2018049124A1 (fr) 2016-09-09 2018-03-15 The General Hospital Corporation Protéine de fusion hsp avec un agent anti-chimiorépulsion pour le traitement d'une maladie infectieuse
WO2018049120A1 (fr) 2016-09-09 2018-03-15 The General Hospital Corporation Cellules présentatrices d'antigène ex vivo ou cellules t cd positives activées pour le traitement du cancer
WO2018049118A1 (fr) 2016-09-09 2018-03-15 The General Hospital Corporation Protéine hsp hybride avec un agent anti-chimiorépulsif pour le traitement du cancer
US11419894B2 (en) 2016-09-16 2022-08-23 The General Hospital Corporation Modified natural killer cells for the treatment of cancer
WO2018106738A1 (fr) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
EP3600395A4 (fr) 2017-03-23 2021-05-05 The General Hospital Corporation Blocage de cxcr4/cxcr7 et traitement d'une maladie associée au papillomavirus humain
WO2018187493A1 (fr) 2017-04-04 2018-10-11 Yale University Compositions et procédés d'administration in utero
AU2018358054A1 (en) 2017-10-31 2020-05-07 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
JP7412341B2 (ja) 2017-10-31 2024-01-12 エディジーン バイオテクノロジー インコーポレイテッド 造血幹細胞および前駆細胞の増幅のための組成物および方法
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2020005878A (es) 2017-12-06 2020-10-07 Magenta Therapeutics Inc Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas.
CN111902411A (zh) 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
WO2020033951A1 (fr) 2018-08-10 2020-02-13 Yale University Compositions et procédés d'édition de gène embryonnaire in vitro
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
WO2020257776A1 (fr) 2019-06-21 2020-12-24 Yale University Compositions d'acides nucléiques peptidiques ayant des segments de liaison de type hoogsteen modifiés et leurs procédés d'utilisation
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2021022161A1 (fr) 2019-07-31 2021-02-04 Yale University Compositions et méthodes de traitement de la drépanocytose
EP4051298A1 (fr) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
EP4143302A1 (fr) 2020-04-27 2023-03-08 Magenta Therapeutics, Inc. Méthodes et compositions pour la transduction de cellules souches et progénitrices hématopoïétiques in vivo
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
US20220031633A1 (en) 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
EP4308694A1 (fr) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation des cellules souches hématopoïétiques en vue d'une greffe de cellules souches chez les patients atteints de myélome multiple
IL311797A (en) 2021-10-01 2024-05-01 Albert Einstein College Of Medicine Methods for increasing stem cell production
CA3240407A1 (fr) 2021-12-08 2023-06-07 Akiko Iwasaki Compositions immunogenes de nanoparticules et methodes de vaccination
WO2023159189A1 (fr) 2022-02-18 2023-08-24 Yale University Polymères de poly(amine-co-ester) ramifiés pour une expression nucléique plus efficace

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) * 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5047572A (en) * 1988-11-18 1991-09-10 Ici Americas Inc. Trisubstituted benzoic acid intermediates
FR2644453A1 (fr) 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
HUT62905A (en) 1989-10-23 1993-06-28 Salutar Inc Process for producing metql complexes comprising polydentate metal chelate forming compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (fr) * 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds

Also Published As

Publication number Publication date
EP0619813B1 (fr) 2004-08-18
CA2125978A1 (fr) 1993-06-24
EP0619813A1 (fr) 1994-10-19
HU9401786D0 (en) 1994-09-28
JPH07501816A (ja) 1995-02-23
ATE273964T1 (de) 2004-09-15
NO2010001I2 (no) 2012-08-27
EP1223166A1 (fr) 2002-07-17
DK0619813T3 (da) 2004-12-20
ES2224096T3 (es) 2005-03-01
HU224013B1 (hu) 2005-04-28
HUT67544A (en) 1995-04-28
IL103984A (en) 1998-10-30
CZ118894A3 (en) 1995-10-18
NZ246179A (en) 1996-03-26
FI942849A0 (fi) 1994-06-15
DE122010000001I1 (de) 2010-08-26
HK1014368A1 (en) 1999-09-24
NO942254D0 (no) 1994-06-15
MX9207316A (es) 1993-06-01
AU3165593A (en) 1993-07-19
HK1049328A1 (zh) 2003-05-09
PT619813E (pt) 2004-12-31
GB9126677D0 (en) 1992-02-12
US5583131A (en) 1996-12-10
FI942849A (fi) 1994-06-15
USRE42152E1 (en) 2011-02-15
NO2010001I1 (no) 2010-03-08
MY110897A (en) 1999-06-30
JP3375961B2 (ja) 2003-02-10
KR100286235B1 (ko) 2001-04-16
CZ286928B6 (cs) 2000-08-16
DE69233401D1 (de) 2004-09-23
PL173643B1 (pl) 1998-04-30
NO305984B1 (no) 1999-08-30
AU661086B2 (en) 1995-07-13
IL103984A0 (en) 1993-05-13
DE69233401T2 (de) 2005-10-13
NL300425I1 (nl) 2010-01-04
RU94031208A (ru) 1996-09-10
NO942254L (no) 1994-06-15
WO1993012096A1 (fr) 1993-06-24
CA2125978C (fr) 2005-09-20

Similar Documents

Publication Publication Date Title
ZA929632B (en) Chemical compounds.
NO933376D0 (no) Morfinan-derivater og medisinsk anvendelse derav
ZA9010184B (en) Anti-viral compositions containing linked polyamines
CA2179530A1 (fr) Polyamines cycliques
AU587372B2 (en) Organic amines containing hydroxyalkyl carbamate groups and method of making the same
HK1003002A1 (en) Analgesic carboxylic acid amide derivatives
GB1384219A (en) 2-alkylamino-dihydropyridines their production and their medicinal use
EP0641763A4 (fr) Nouveaux sels d'ammonium quaternaires et utilisation de ces sels comme medicament.
ES2018420A6 (es) Procedimiento para preparar derivados sustituidos de alilaminas.
TH3422A (th) สารประกอบ
TH13338EX (th) อนุพันธ์ n-เอซิล-(สูตรเคมี)-อมิโนแอซิด
TH13390A (fr)
TH13795A (th) อนุพันธ์กวานิดีน
HUT39418A (en) Process for producing disubstituted carbodiimides
GB948897A (en) Heterocyclic amine compounds and method of producing the same
TH1033A (th) การใช้ไนโตร อะมิโน และเอโรอิลอะมิโน-n- เฟนนิลพิริดีนอะมีนในกรรมวิธีการเตรียมสารพิริโด [1,4] -เบนโซไดอะซิฟินซึพีนต่าง ๆ
FR2244495A1 (en) 3-Amino-1,5-bis(3,4-methylenedioxyphenyl)pentanes - with myolytic activity for treating convulsion of smooth muscle